| ImmuCell Corporation (ICCC) Q1 2025 Earnings Call Transcript |
ImmuCell Corporation (NASDAQ:ICCC ) Q1 2025 Earnings Conference Call May 15, 2025 9:00 AM ET Company Participants Joe Diaz - Managing Partner, Lytham Partners, LLC Michael Brigham - President & Chief Executive Officer Tim Fiori - Chief Financial Officer Conference Call Participants George Melas - MKH Management Russ Tolander - Capital Alliance Operator Good morning and welcome to the ImmuCell Corporation Reports First Quarter Ended March 31st, 2025 Audited Financial Results Conference Call. All participants will be in listen-only mode. |
seekingalpha.com |
2025-05-15 14:19:51 |
Czytaj oryginał (ang.) |
| ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025 |
PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2025. |
globenewswire.com |
2025-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025 |
PORTLAND, Maine, May 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2025 after the market closes on Wednesday, May 14, 2025. The Company is planning to host a conference call the next morning, Thursday, May 15, 2025, at 9:00 AM ET to review the unaudited financial results. |
globenewswire.com |
2025-05-12 12:42:00 |
Czytaj oryginał (ang.) |
| ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025 |
PORTLAND, Maine, April 08, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2025. |
globenewswire.com |
2025-04-08 20:05:00 |
Czytaj oryginał (ang.) |
| ImmuCell Announces Initiation of Investigational Product Use of Re-Tain® |
PORTLAND, Maine, April 02, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it is initiating Investigational Product use of Re-Tain ®. |
globenewswire.com |
2025-04-02 20:05:00 |
Czytaj oryginał (ang.) |
| ImmuCell Posts Y/Y Q4 Earnings Growth, Awaits FDA Approval for Re-Tain |
ImmuCell posts 52% y/y sales growth in Q4. It improves margins and eyes FDA approval for Re-Tain to drive expansion. |
zacks.com |
2025-02-28 16:00:33 |
Czytaj oryginał (ang.) |
| ImmuCell Corporation (ICCC) Q4 2024 Earnings Call Transcript |
ImmuCell Corporation (NASDAQ:ICCC ) Q4 2024 Earnings Conference Call February 26, 2025 9:00 AM ET Company Participants Joe Diaz - Managing Partner, Lytham Partners, LLC Michael Brigham - President and Chief Executive Officer Conference Call Participants George Melas-Kyriazi - MKH Management Operator Good morning, and welcome to ImmuCell Corporation Reports its Fourth Quarter and Year Ended December 31, 2024, Unaudited Financial Results Conference Call. All participants will be in listen-only mode. |
seekingalpha.com |
2025-02-26 13:44:02 |
Czytaj oryginał (ang.) |
| ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024 |
PORTLAND, Maine, Feb. 25, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter and year ended December 31, 2024. |
globenewswire.com |
2025-02-25 18:05:00 |
Czytaj oryginał (ang.) |
| ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024 |
Conference Call Scheduled for Wednesday, February 26, 2025 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 26, 2025 at 9:00 AM ET |
globenewswire.com |
2025-02-20 10:19:00 |
Czytaj oryginał (ang.) |
| ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses |
PORTLAND, Maine, Jan. 16, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has settled an insurance claim covering some of the losses incurred from production contamination events. |
globenewswire.com |
2025-01-16 18:05:00 |
Czytaj oryginał (ang.) |
| ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024 |
PORTLAND, Maine, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the fourth quarter and full year ended December 31, 2024. |
globenewswire.com |
2025-01-09 18:05:00 |
Czytaj oryginał (ang.) |
| Zacks Initiates Coverage of ImmuCell With Neutral Recommendation |
Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates ImmuCell as "Neutral." Explore ImmuCell's market leadership, growth prospects and the game-changing potential of its mastitis treatment nearing FDA approval. |
zacks.com |
2024-12-04 10:51:07 |
Czytaj oryginał (ang.) |
| ImmuCell Q3 Earnings Decline Y/Y, Sales Grow Amid Margin Challenges |
ICCC sees strong Q3 sales growth but faces challenges with margins. It awaits FDA approval for its groundbreaking Re-Tain product. |
zacks.com |
2024-11-19 14:21:20 |
Czytaj oryginał (ang.) |
| ImmuCell Corporation (ICCC) Q3 2024 Earnings Call Transcript |
ImmuCell Corporation (NASDAQ:ICCC ) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Company Participants Joe Diaz - Lytham Partners Michael Brigham - President and CEO Conference Call Participants George Melas - MKH Management Operator Good morning and welcome to ImmuCell Corporation Reports Third Quarter September 30, 2024, Unaudited Financial Results Conference Call. All participants will be in listen-only mode. |
seekingalpha.com |
2024-11-14 13:09:10 |
Czytaj oryginał (ang.) |
| ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024 |
PORTLAND, Maine, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2024. |
globenewswire.com |
2024-11-13 18:05:00 |
Czytaj oryginał (ang.) |
| ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024 |
Conference Call Scheduled for Thursday, November 14, 2024 at 9:00 AM ET Conference Call Scheduled for Thursday, November 14, 2024 at 9:00 AM ET |
globenewswire.com |
2024-11-07 10:30:00 |
Czytaj oryginał (ang.) |
| ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024 |
PORTLAND, Maine, Oct. 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2024, which ended September 30, 2024. |
globenewswire.com |
2024-10-08 20:05:00 |
Czytaj oryginał (ang.) |
| ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2024 |
PORTLAND, Maine, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2024. |
globenewswire.com |
2024-08-13 20:05:00 |
Czytaj oryginał (ang.) |
| ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2024 |
Conference Call Scheduled for Wednesday, August 14, 2024 at 9:00 AM ET Conference Call Scheduled for Wednesday, August 14, 2024 at 9:00 AM ET |
globenewswire.com |
2024-08-07 20:05:00 |
Czytaj oryginał (ang.) |
| ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2024 |
PORTLAND, Maine, July 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2024, which ended June 30, 2024. |
globenewswire.com |
2024-07-09 20:05:00 |
Czytaj oryginał (ang.) |
| ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain® |
PORTLAND, Maine , June 05, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today provided a regulatory update on the status of its product development initiative for Re-Tain ®. |
globenewswire.com |
2024-06-05 20:05:00 |
Czytaj oryginał (ang.) |
| ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders |
PORTLAND, Maine, June 04, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2024 Annual Meeting of Stockholders (the “Annual Meeting”) will be conducted virtually on Thursday, June 13, 2024, at 9:30 AM ET, as previously disclosed in its Proxy Statement filed with the Securities and Exchange Commission (“SEC”) on April 26, 2024. |
globenewswire.com |
2024-06-04 20:05:00 |
Czytaj oryginał (ang.) |
| ImmuCell Corporation (ICCC) Q1 2024 Earnings Call Transcript |
ImmuCell Corporation (NASDAQ:ICCC ) Q1 2024 Results Conference Call May 15, 2024 9:00 AM ET Company Participants Joe Diaz - Lytham Partners Michael Brigham - President & CEO Conference Call Participants Michael Potter - Monarch Capital Group Maynard Fernandez - McDill Columbus Sean Kirkwood - SRK Capital Operator Good morning, and welcome to the ImmuCell Corporation Reports First Quarter ended March 31, 2024 Unaudited Financial Results Conference Call. All participants are in a listen-only mode. |
seekingalpha.com |
2024-05-15 17:48:05 |
Czytaj oryginał (ang.) |
| ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024 |
PORTLAND, Maine, May 14, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2024. |
globenewswire.com |
2024-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024 |
PORTLAND, Maine, May 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2024 after the market closes on Tuesday, May 14, 2024. The Company is planning to host a conference call the next morning, Wednesday, May 15, 2024, at 9:00 AM ET to review the unaudited financial results. |
globenewswire.com |
2024-05-08 17:00:00 |
Czytaj oryginał (ang.) |
| ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024 |
PORTLAND, Maine, April 09, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2024, which ended March 31, 2024. |
globenewswire.com |
2024-04-09 20:05:00 |
Czytaj oryginał (ang.) |
| ImmuCell Corporation (ICCC) Q4 2023 Earnings Call Transcript |
ImmuCell Corporation (ICCC) Q4 2023 Earnings Call Transcript |
seekingalpha.com |
2024-02-28 13:58:06 |
Czytaj oryginał (ang.) |
| ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023 |
PORTLAND, Maine, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter and year ended December 31, 2023. |
globenewswire.com |
2024-02-27 18:05:00 |
Czytaj oryginał (ang.) |
| ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2023 |
Conference Call Scheduled for Wednesday, February 28, 2024 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 28, 2024 at 9:00 AM ET |
globenewswire.com |
2024-02-16 11:30:00 |
Czytaj oryginał (ang.) |
| ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 2023 |
PORTLAND, Maine, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the fourth quarter of 2023, which ended December 31, 2023. |
globenewswire.com |
2024-01-08 18:05:00 |
Czytaj oryginał (ang.) |
| ImmuCell Corporation (ICCC) Q3 2023 Earnings Call Transcript |
ImmuCell Corporation (NASDAQ:ICCC ) Q3 2023 Earnings Conference Call November 14, 2023 9:00 AM ET Company Participants Joe Diaz - Managing Partner; Lytham Partners, LLC Michael Brigham - CEO Conference Call Participants Operator Good day, everyone, and welcome to the ImmuCell Corporation's Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded. |
seekingalpha.com |
2023-11-14 16:36:22 |
Czytaj oryginał (ang.) |